Tissue Regeneration Systems (TRS) is a start-up medical device company commercializing a breakthrough skeletal reconstruction and bone regeneration technology platform licensed from the Universities of Michigan and Wisconsin. Our technology has been evaluated in several large animal studies with very promising long term results. We have completed all required bench and animal testing and received 510K approval from the FDA, clearing both our technology platform and our first product for commercialization in the United States. In order to fully capitalize on the broad range of clinical opportunities for our technology platform, TRS has chosen to pursue a corporate partnership business model. We recently established a fully integrated, FDA-compliant manufacturing operation to support this strategy.